loading page

Metabolomics reveals molecular signatures for psoriasis biomarkers and drug targets discovery
  • liu jie
liu jie
BGI-Shenzhen

Corresponding Author:[email protected]

Author Profile

Abstract

Background Plasma metabolomic analysis can provide a great deal of information on potential diagnostic biomarkers, pathogenesis and personalized treatment. Psoriasis is a chronic, multi-system skin disease that can be influenced by immunological, environmental, and genetic factors. However, the role of metabolites in psoriasis is unknown. Objective To deepen the understanding of the pathogenesis of psoriasis in metabolites and to screen potential biomarkers and therapeutic target proteins for auxiliary diagnosis and treatment of the disease. Methods We performed an untargeted metabolomic analysis of plasma based on high-resolution liquid chromatography mass spectrometry from 10 plaque psoriasis patients and 10 healthy controls. Results A total of 301 differential metabolites were detected, of which 10 metabolites were potential biomarkers, including vitamins, amino acids, and lipids. At the same time, KEGG pathway enrichment analysis was performed for all detected differential metabolites, and it was found that protein digestion and absorption, amino acid metabolism and lipid metabolism may be jointly involved in regulating the pathogenesis of psoriasis. In addition, the proteins ESR1, OPRM1 and HSD11B1 were identified as potential topical therapeutic targets for psoriasis through analysis of the metabolite-protein interaction network. Conclusions In this study, we identified 10 differential metabolites as potential combinatorial biomarkers for the diagnosis of psoriasis. 12 metabolic pathways were significantly enriched that may be closely related to the occurrence and development of psoriasis. Three proteins, ESR1, OPRM1, and HSD11B1, were identified as potential therapeutic targets for psoriasis.